drugset
Drugs / Heparin
last change 10 days ago re-read 8 days ago

Heparin

also known as Heparin Sodium · unfractionated heparin · UFH · sodium heparin · Heparin sodium APP · Heparin Sodium Injection, USP · Heparine · Porcine sodium heparin · +29 more

Other / unclassified

Developed for
COVID-19 · venous thromboembolism · interstitial cystitis · myocardial infarction · pulmonary embolism · acute lung injury · infectious disease with sepsis · intermediate coronary syndrome
+50 more · pneumonia · acute respiratory distress syndrome · arteriovenous hemangioma/malformation · brain aneurysm · cardiac valvular defect · coronary artery disorder · ischemic stroke · morbid obesity · prosthesis-related infectious disease · thrombophilia · thrombotic disease · urinary tract infection · abdominal aortic aneurysm · acute intestinal ischemia · anaphylaxis · angioedema · arterial disorder · arterial occlusion · atrial fibrillation · cardiogenic shock · cirrhosis of liver · colorectal cancer · congenital total pulmonary venous return anomaly · disseminated intravascular coagulation · ischemic disease · isolated mesenteric vein thrombosis · pelvis syndrome · peripheral vascular disease · pregnancy disorder · pregnancy loss, recurrent, 4 · ST-elevation myocardial infarction · viral pneumonia · vulvodynia · acquired aneurysmal subarachnoid hemorrhage · acute coronary syndrome · acute kidney injury · acute myocardial infarction · adhesions of uterus · cerebral sinovenous thrombosis · chronic renal failure syndrome · coronary artery intramyocardial course · dialysis disequilibrium syndrome · end stage renal failure · habitual spontaneous abortion · heart disorder · impaired renal function disease · intracranial embolism · portal vein thrombosis · type 1 diabetes mellitus · vascular occlusion disorder
Investigated by
Azidus Brasil · Blau Farmaceutica S.A. · Frederick Health · Guangdong Provincial People's Hospital · National Cancer Institute (NCI) · Scripps Health
+181 more · Shanghai First Maternity and Infant Hospital · Swedish Orphan Biovitrum · University Health Network, Toronto · University Medicine Greifswald · University of Manitoba · Urigen · West China Hospital · Academic Medical Center - University of Amsterdam · Adiyaman University Research Hospital · Ain Shams University · American College of Emergency Physicians · Amsterdam UMC, location VUmc · Anlu People's Hospital · Assistance Publique - Hôpitaux de Paris · Assiut University · Astes · Australian and New Zealand Intensive Care Research Centre · Azienda Ospedaliera di Lecco · Basma Rabiey · Baylor Research Institute · Beijing Friendship Hospital · Beijing Tiantan Hospital · Beijing Tsinghua Changgeng Hospital · Berry Consultants · Boehringer Ingelheim · Boston Children's Hospital · Brittany Bissell · Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME · C. Clay Cothren, MD · CR & WISCO General Hospital · Caidian People's Hospital · Cedars-Sinai Medical Center · Centocor, Inc. · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · Chen Ying · Chibi General Hospital · China Medical University, China · Clinica San Camilo, Argentina · Clinical Centre of Serbia · Columbia University · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Consorci Sanitari de l'Alt Penedès i Garraf · CorMedix · CorMedix Therapeutics · Daiichi Sankyo · Damian Ratano · Dijklander Ziekenhuis · Duke University · Emergency Physicians Foundation of KC · Endeavor Health · Ezhou Central Hospital · FDA Office of Orphan Products Development · Fatemeh Hoseinzadegan · Fifth Hospital in Wuhan · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Fujian Medical University · First Affiliated Hospital of Harbin Medical University · First Affiliated Hospital of Kunming Medical University · Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy · Fourth People's Hospital of Shenyang · Fujian Medical University Union Hospital · General Hospital of Ningxia Medical University · General Hospital of Yangtze River shipping · German Heart Center Munich · Global Coalition for Adaptive Research · Guoyao Dongfeng General Hospital · Hanyang University · Hubei University of Medicine · Hubei Zhongshan Hospital · Intensive Care National Audit & Research Centre · Jiangling People's Hospital · Jiangxia First People's Hospital · Jingzhou Central Hospital · Johns Hopkins University · all 187 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER — 1989-06-23 fda.gov ↗
Label expansions (3) US (FDA) HEPARIN SODIUM — 1983-12-19 – 1986-04-11 fda.gov ↗
Label expansion US (FDA) HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER — 1985-07-09 fda.gov ↗
Label expansions (2) US (FDA) HEPARIN LOCK FLUSH — 1981-05-15 – 1985-05-21 fda.gov ↗
Approved US (FDA) HEPARIN SODIUM — 1939-02-09 fda.gov ↗

Trials 105 · started per year

today
US approved 1939
1
1
1
1
1
4
1
1
3
3
6
4
4
4
8
2
7
5
5
6
2
11
6
3
7
2
3
1
193719381939194019411942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT06112262 Dec 2023 → Sep 2025 overdue — Basma Rabiey Not yet recruiting No outcome recorded
Phase 0 NCT05178550 Dec 2021 → Jan 2022 — Novo Nordisk A/S Completed No outcome recorded
Phase 0 NCT04490239 Oct → Nov 2020 COVID-19 Joshua Sharp Completed No outcome recorded
Phase 0 NCT02246270 Nov 2017 → Dec 2025 urinary tract infection University of Oklahoma Completed No outcome recorded
Phase 0 NCT02970032 Nov 2016 → Sep 2017 pulmonary embolism, venous thromboembolism University of Utah Completed No outcome recorded
Phase 110 trials
Phase 1 NCT05788913 Jun 2023 — Blau Farmaceutica S.A. Unknown No outcome recorded
Phase 1 NCT05788900 Jun 2023 — Blau Farmaceutica S.A. Unknown No outcome recorded
Phase 1 NCT03125187 Feb 2021 — Uniao Quimica Suspended No outcome recorded
Phase 1 NCT02435732 Dec 2020 → May 2021 kidney failure University of Wisconsin, Madison Unknown No outcome recorded
Phase 1 NCT02271126 Sep 2014 → Sep 2016 — Policlinico Hospital Completed No outcome recorded
Phase 1 NCT01651923 Feb → Apr 2013 — Azidus Brasil Unknown No outcome recorded
Phase 1 NCT01652638 Feb → Apr 2013 — Azidus Brasil Unknown No outcome recorded
Phase 1 NCT01598883 Jun 2012 → Dec 2014 — Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT01163097 Jul 2010 → Jan 2011 mucositis Swedish Orphan Biovitrum Completed No outcome recorded
Phase 1 NCT00361348 Dec 2005 → Jul 2006 — Swedish Orphan Biovitrum Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT04511923 Dec 2020 → Dec 2021 COVID-19, acute lung injury, acute respiratory distress syndrome University College Hospital Galway Completed No outcome recorded
Phase 1/2 NCT04397289 Feb 2018 → Mar 2021 cirrhosis of liver, hemorrhagic disease, portal hypertension, thrombotic disease First Affiliated Hospital Xi'an Jiaotong University Completed No outcome recorded
Phase 1/2 NCT02940444 Jun 2016 → Jun 2018 venous thromboembolism West China Hospital Unknown No outcome recorded
Phase 211 trials
Phase 2 NCT06381661 May 2026 → Jun 2028 expected infectious disease with sepsis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT06080074 Apr 2025 → Sep 2027 expected cardiogenic shock, cardiomyopathy, congenital heart disease, heart failure Stanford University Recruiting No outcome recorded
Phase 2 NCT05737121 May 2023 → Jun 2026 overdue interstitial cystitis Vaneltix Pharma, Inc. Recruiting No outcome recorded
Phase 2 NCT07074821 Mar 2023 → Feb 2024 — Oman Ministry of Health Completed No outcome recorded
Phase 2 NCT04842292 May → Sep 2021 COVID-19 Brittany Bissell Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT03633994 Aug 2018 → Dec 2019 urinary tract infection The Christ Hospital Unknown No outcome recorded
Phase 2 NCT02591199 Sep 2015 → May 2018 interstitial cystitis Urigen Terminated No outcome recorded Stop: Business
Phase 2 NCT01048177 Dec 2012 → Jun 2014 vulvodynia Scripps Health Withdrawn No outcome recorded
Phase 2 NCT00317070 Apr 2006 → Feb 2009 interstitial cystitis Nova Scotia Health Authority Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00256542 Jan → Sep 2006 interstitial cystitis, pelvis syndrome Urigen Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT04273607 Sep 2022 → Dec 2026 expected — Damian Ratano Recruiting No outcome recorded
Phase 2/3 NCT04372589 May 2020 → May 2021 COVID-19, pneumonia University of Manitoba Completed Mixed
Phase 2/3 NCT02040818 Nov 2013 → Jan 2017 — University of California, San Diego Withdrawn No outcome recorded Stop: Enrollment
Phase 2/3 NCT01034488 Aug 2010 → Dec 2011 — Azidus Brasil Unknown No outcome recorded
Phase 2/3 NCT00701623 Jun 2008 — Azidus Brasil Withdrawn No outcome recorded
Phase 319 trials · 2 met primary · 1 missed
Phase 3 NCT07162064 Aug 2025 → Jan 2026 ischemic stroke Xiang Luo Completed No outcome recorded
Phase 3 NCT05886998 Jun 2023 → Jun 2024 acute lung injury Ain Shams University Completed No outcome recorded
Phase 3 NCT04600141 Nov 2020 → Oct 2021 COVID-19 University of Sao Paulo Completed No outcome recorded
Phase 3 NCT02654561 Apr 2018 → Dec 2024 disseminated intravascular coagulation, infectious disease with sepsis China Medical University, China Unknown No outcome recorded
Phase 3 NCT02798471 Mar 2017 → May 2022 pulmonary embolism, venous thromboembolism Daiichi Sankyo Completed No outcome recorded
Phase 3 NCT02735707 Apr 2016 → Feb 2026 overdue pneumonia UMC Utrecht Recruiting Mixed
Phase 3 NCT02036255 May 2015 → Jul 2017 infectious disease University Hospital Brussels Completed Met primary
Phase 3 NCT01976988 Sep 2013 → May 2015 venous thromboembolism Cedars-Sinai Medical Center Completed Missed primary
Phase 3 NCT01454869 Feb → Jun 2012 — Tehran University of Medical Sciences Withdrawn No outcome recorded Stop: Business
Phase 3 NCT00912483 May → Nov 2010 venous thromboembolism Azidus Brasil Withdrawn No outcome recorded
Phase 429 trials · 1 met primary · 3 missed
Phase 4 NCT06714864 Jul 2025 → Jul 2028 expected prosthesis-related infectious disease CorMedix Therapeutics Recruiting No outcome recorded
Phase 4 NCT04723563 Feb → Aug 2021 COVID-19, viral pneumonia Frederick Health Completed No outcome recorded
Phase 4 NCT04505774 Sep 2020 → Aug 2023 COVID-19 Matthew Neal MD Completed Missed primary
Phase 4 NCT04397510 Jun 2020 → Dec 2021 COVID-19, acute lung injury, acute respiratory distress syndrome Frederick Health Terminated No outcome recorded Stop: Enrollment
Phase 4 NCT04530578 Jun → Oct 2020 COVID-19, pneumonia Clinica San Camilo, Argentina Unknown No outcome recorded
Phase 4 NCT04367831 May 2020 → May 2021 COVID-19, thrombotic disease, venous thromboembolism Columbia University Completed No outcome recorded
Phase 4 NCT04061798 Mar 2020 → Apr 2024 abdominal aortic aneurysm Dijklander Ziekenhuis Terminated No outcome recorded
Phase 4 NCT03752437 Oct 2019 → Sep 2021 — Astes Completed No outcome recorded
Phase 4 NCT04496362 Oct 2018 → Feb 2025 overdue respiratory failure Baylor Research Institute Active not recruiting No outcome recorded
Phase 4 NCT03006562 Jul 2017 → Nov 2019 lymphocele, prostate cancer, pulmonary embolism, venous thromboembolism Johns Hopkins University Terminated Missed primary
Phase not applicable22 trials · 1 missed
— NCT06549842 Aug 2024 → Feb 2026 arterial occlusion, hemorrhagic disease Regional Hospital of Scranton Completed No outcome recorded
— NCT05634057 Jan 2024 → Dec 2025 overdue infectious disease with sepsis Chen Ying Recruiting No outcome recorded
— NCT05749393 Apr 2023 → Mar 2024 brain aneurysm The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
— NCT05329155 Jul 2022 → Aug 2023 ST-elevation myocardial infarction Renmin Hospital of Wuhan University Completed No outcome recorded
— NCT05209841 Apr 2022 → Jul 2026 overdue — Consorci Sanitari de l'Alt Penedès i Garraf Recruiting No outcome recorded
— NCT04764396 Mar → Apr 2021 pancreatic neoplasm University of Michigan Terminated No outcome recorded Stop: Business
— NCT04767113 Mar 2021 → Aug 2022 venous thromboembolism Guangdong Provincial People's Hospital Completed Missed primary
— NCT04241380 Feb 2020 → Oct 2021 congenital total pulmonary venous return anomaly Guangdong Provincial People's Hospital Unknown No outcome recorded
— NCT04227678 Dec 2019 → Dec 2026 expected familial lipoprotein lipase deficiency University of Sherbrooke Recruiting No outcome recorded
— NCT03483207 Apr 2018 → Dec 2019 isolated mesenteric vein thrombosis Assiut University Unknown No outcome recorded
Phase not stated1 trial
— NCT06707480 — — CorMedix No longer available No outcome recorded
Comparator or background therapy158 trials
Phase 0 NCT05029596 Comparator Feb 2020 → Mar 2023 cancer University of Texas Southwestern Medical Center Completed No outcome recorded
Phase 0 NCT03516656 Comparator Mar 2018 → Jun 2019 pulmonary embolism, venous thromboembolism University of Utah Completed No outcome recorded
Phase 1 NCT07759167 Background Sep 2026 → Apr 2027 expected end stage renal failure Regeneron Pharmaceuticals Recruiting No outcome recorded
Phase 1 NCT03707418 Comparator Apr → Jun 2021 — Johns Hopkins University Withdrawn No outcome recorded Stop: Business
Phase 1 NCT04419493 Background Jun 2020 → Jun 2021 — Boehringer Ingelheim Completed Met primary
Show all 158 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 7

DateIssuerRelease
2024-06-06 CorMedix Regulatory CORMEDIX INC. ANNOUNCES CMS GRANTS PASS-THROUGH STATUS TO DEFENCATH cormedix.com ↗
today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS).
2024-04-19 CorMedix Regulatory CORMEDIX INC. ANNOUNCES CMS GRANTS TDAPA TO DEFENCATHDefenCath® (taurolidine and heparin)IMPORTANT SAFETY INFORMATION cormedix.com ↗
CMS determination of TDAPA eligibility for DefenCath is a critical step toward ensuring this innovative preventative drug product is available for patients in the outpatient dialysis setting.
2023-11-15 CorMedix Regulatory CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE THE INCIDENCE OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT HEMODIALYSIS PATIENTS cormedix.com ↗
DefenCath is the first and only FDA-approved antimicrobial CLS in the U.S. and was shown to reduce the risk of CRBSIs by up to 71% in a Phase 3 clinical study.
2023-05-16 CorMedix Regulatory CORMEDIX INC. ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH cormedix.com ↗
today announced that the New Drug Application for DefenCath was resubmitted to the U.S. Food and Drug Administration, and the submission has been acknowledged as received for processing.
2021-11-16 Rockwell Medical Technologies, Inc. Results Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin rockwellmed.com ↗
2021-03-01 CorMedix Regulatory CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION cormedix.com ↗
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) cannot approve the New Drug Application (NDA) for DefenCath™ (taurolidine/heparin catheter lock solution) in its present form.
2015-03-30 Janssen Research & Development, LLC Results New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO® Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits jnj.com ↗
A 27 percent reduction in hospital admissions when patients were treated with XARELTO® instead of LMWH and warfarin (p<0.001).

All press releases naming this drug 11 releases

DateIssuerRelease

Evidence & citations 41 cited values

Every value below carries the sentence it was read from. 273 sources stand behind the page.

FieldValueCited text
Known as Heparin “Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus...” NCT03463915 ↗
231

“standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids” NCT01718288 ↗

“1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH” NCT02868697 ↗

“If participant falls in LD heparin group, he/she will receive IV heparin 2000-3000 IU (\<60 Kg-2000 IU; 60-80 Kg-2500 IU; \>80 Kg-3000 IU) at the start of CAG” NCT05591872 ↗

“prime solution containing Ringer-Acetate 1000 ml + Mannitol 400 ml (60 g) + Sodium-Chloride 40 ml (160 mmol) and Heparin 2 ml (10 000 IU)” NCT05914896 ↗

“Heparin: Nebulized heparin has been proposed as a treatment for ARDS patients due to its anti-inflammatory and anticoagulant effects.” NCT07286409 ↗

“Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen” NCT03395639 ↗

“continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s)” NCT04241380 ↗

“intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%” NCT01074567 ↗

“Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.” NCT03537586 ↗

“Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.” NCT00790842 ↗

Show 221 more sources
Known as Actparin “The purpose of this study is to investigate clinical non-inferiority, pharmacodynamic effect and safety of Actparin® (heparin sodium - Laboratório Químico Farmacêutico Bergamo...” NCT01346215 ↗
Known as Alimax “Clinical Efficacy of Product Alimax ® (Sodic Heparin) in Treatment of Burns: Comparative Study of Raw Materials Between Two Suppliers” NCT00701623 ↗
Known as APP Sodium heparin = Sodium heparin (App Pharmaceuticals) “APP Sodium heparin = Sodium heparin (App Pharmaceuticals)” NCT01652638 ↗
Known as Fibrilin TM “Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter” NCT01229592 ↗
Known as Fibrillin “Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)” NCT05209841 ↗
Known as Hepalean “Hepalean Heparin” NCT01343381 ↗
Known as Hepamax-S = Sodium heparin (Blau Farmacêutica S/A) “Hepamax-S = Sodium heparin (Blau Farmacêutica S/A)” NCT01652638 ↗
Known as Heparin calcium ClinicalTrials.gov intervention name — accepted as the source's own label NCT01051778 ↗
Known as Heparin sodic “Heparin sodic - Cristália” NCT00828776 ↗
Known as Heparin Sodium “The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed...” NCT01651923 ↗
30

“The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine...” NCT02591199 ↗

“Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in...” NCT02181985 ↗

“Current guidelines recommended either heparin sodium (unfractionated heparin) or low-molecular-weight heparin (LMWH) for those patients at high risk of deep vein thrombosis (DVT).” PMID 28523161 ↗ Apr 2017

“Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.” NCT06055920 ↗

“Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.)” NCT03333395 ↗

“The investigators are investigating the tolerability of Heparin Sodium (porcine) administered topically via a nasal spray.” NCT04490239 ↗

“Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation” NCT05737121 ↗

“Heparin Sodium, 1000 Units/mL Injectable Solution 1” NCT04054128 ↗

“Heparin sodium (Generic, 5000 IU/ml ampoules)” NCT05886998 ↗

NCT01352039 ↗

Show 20 more sources
Known as Heparin Sodium (porcine) “The investigators are investigating the tolerability of Heparin Sodium (porcine) administered topically via a nasal spray.” NCT04490239 ↗
Known as Heparin Sodium - APP Pharmaceuticals “Heparin Sodium - APP Pharmaceuticals” NCT01352039 ↗
Known as heparin sodium - blausiegel “heparin sodium - blausiegel” NCT00894985 ↗
Known as Heparin Sodium - Eurofarma “Heparin Sodium - Eurofarma” NCT01352039 ↗
Known as Heparin sodium APP “Heparin sodium APP 5.000 USP” NCT00894959 ↗
2

“Heparin sodium APP 5.000 USP” NCT00894829 ↗

“heparin sodium - APP” NCT00894985 ↗
Known as Heparin sodium Blausiegel 1 “Heparin sodium Blausiegel 1 5.000 UI” NCT00894959 ↗
Known as Heparin Sodium Injection “the drug is Heparin Sodium Injection 2ml:12500 Units per bottle” NCT06365398 ↗
Known as Heparin Sodium Injection, USP “Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/ 0.5 mL; Fresenius Kabi Lake Zurich.” NCT05788913 ↗
1

“Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/mL; Fresenius Kabi Lake Zurich.” NCT05788900 ↗
Known as Heparin Sodium USP “Supplier The test article (Heparin Sodium USP) will be obtained from appropriate commercial sources.” NCT04490239 ↗
Known as Heparin sulfate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00779558 ↗
Known as heparin sulphate “heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be...” NCT02870738 ↗
Known as Heparin, Low-Molecular-Weight ClinicalTrials.gov intervention name — accepted as the source's own label NCT00577096 ↗
Known as Heparin-Natrium-5000-ratiopharm “Heparin-Natrium-5000-ratiopharm (unfractionated heparin)” NCT04419493 ↗
Known as Heparine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132689 ↗
1

NCT02411331 ↗